GlobalData’s report assesses the drugs in the Bile Acid Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

In its present supplemental new drug application ... Given that obeticholic acid decreases bile acid synthesis, the ...

Bile acids were first described chemically in 1849 ... We think they, or the bacteria that make them, may make good drug candidates — the ‘bugs as drugs’ idea. You could engineer bacterial ...

Mirum's purchase of Travere Therapeutics (TVTX) bile acid portfolio may have been an opportunistic move, as Travere was looking for a quick sale to fund development of its kidney disease drug ...

The Breakthrough Therapy designation is supported by positive interim data from the phase 2b VANTAGE study (ClinicalTrials.gov Identifier: NCT05050136) that evaluated the efficacy and safety of ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

Bile acid reflux could result from bariatric (weight ... Managing stress involves measures such as: Prescription drugs are ...

Novartis’ most advanced FXR agonists, are non-bile acid drugs and are in phase 2 clinical trials. Both have received Fast Track designation from the FDA for NASH with liver fibrosis. The FDA has ...

In 1902 a Swedish scientist isolated one of the chemicals in bear bile, later named ursodeoxycholic acid, and it’s now used in drugs for liver diseases and gallstones. But Iaizzo and other ...

Pale or clay-colored poop can occur due to an underlying biliary condition, liver disease, gallbladder problems, tumors, or ...

Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda ...